Could Low-Nicotine smokes plus E-Cigs cut harm for mentally ill smokers?
NCT ID NCT04058717
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looked at whether using very low nicotine cigarettes along with nicotine-containing e-cigarettes can reduce harmful chemical exposure in smokers with mental health conditions. 88 participants were assigned to different combinations of cigarettes and e-cigarettes. The main goal was to measure a cancer-related chemical in urine and other markers of smoke exposure.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Very low nicotine cigarettes and nicotine-containing e-cigarettes
- What this could lead to
- If successful, this could point toward ways to reduce harmful chemical exposure in smokers who cannot or will not quit.
- What could go wrong
- This is a small, early-stage study with only 88 participants, so results may not apply to all smokers. It does not test quitting or long-term health outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
88 people
The number who actually took part.
- Started
-
Jun 2021
- Finished
-
Aug 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
21 to 70 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Smoke \>5 cigarettes per day for at least the prior 12 months * Smoke regular, filtered cigarettes or machine-rolled cigarettes with a filter * Exhaled CO measurement of ≥ 6 parts per million at baseline * No serious cigarette smoking quit attempt or use of any FDA-approved smoking cessation medication in the prior 30 days (includes any nicotine replacement, varenicline, bupropion \[used specifically as a quitting aid\]) * No plans to quit smoking within the next 3 weeks * Must be willing to both switch to a different type of cigarette that may contain a different amount of nicotine and to try an e-cig to substitute for some of their cigarettes * Must be willing and able to respond to contacts from study staff or attend visits over the study period (not planning to move, not planning extended vacation, no planned surgeries) * 9\. Must meet lifetime diagnostic criteria for a current or lifetime unipolar or bipolar mood disorder (e.g. major depressive disorder, major depressive episode, manic episode, hypomanic episode, bipolar disorder), an anxiety disorder (e.g. panic disorder, obsessive-compulsive disorder, post-traumatic stress disorder, , agoraphobia, social anxiety disorder, generalized anxiety disorder), a psychotic disorder (e.g. mood disorder or other psychotic disorder), or an eating disorder (e.g. anorexia or bulimia) based on the MINI-International Neuropsychiatric Interview Standard (MINI) (version 7.0.2) * Able to read and write in English * Able to understand and give informed consent * Access to a computer/smartphone with e-mail and a reliable internet connection Exclusion Criteria: * Women who are pregnant and/or nursing or trying to become pregnant * Unstable or significant medical condition in the past 3 months (e.g., recent heart attack or other serious heart condition, stroke, severe angina, high blood pressure \[systolic \>159 mmHg or diastolic \>99 mmHg during screening) * Respiratory diseases (e.g., exacerbations of asthma or COPD, require oxygen, require oral prednisone), kidney (e.g., dialysis) or liver disease (e.g., cirrhosis), severe immune system disorders (e.g., uncontrolled HIV/AIDS, multiple sclerosis symptoms) or any medical disorder/medication that may affect participant safety or biomarker data * Uncontrolled mental illness or substance abuse, or inpatient treatment for these in the past 6 months * Current suicide risk on clinical assessment (above "low risk" score (or ≥ 9) on MINI diagnostic interview suicide module during screening (34)) * Use of any non-cigarette nicotine delivery product (e.g., pipe, cigar, dip, chew, snus, hookah, e-cig, strips or sticks, IQOS) in the past 7 days at screening * Use of an e-cig for 5 or more days in the past 28 days or any use in the past 7 days at screening * Use of marijuana or other illegal drugs/prescription drugs for non-medical use daily/almost daily or weekly in the past 3 months per NIDA Quick Screen * Any known allergy to propylene glycol or vegetable glycerin * Surgery requiring general anesthesia in the past 6 weeks * Unwilling to remain on one flavor of cigarette (regular or menthol) for the duration of the trial * Previous use of SPECTRUM research cigarettes in the past 6 months * Other member of household currently participating in the study * History of a seizure disorder or had a seizure in the past 12 months * Currently taking or have taken medications prescribed to prevent seizures (such as Carbamazepine or Phenobarbital). Using seizure medications for off-label use (indications other than treatment for seizures) will not be included as an exclusion, these will be assessed on a case-by-case basis
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Anxiety disorder are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Penn State College of Medicine
Hershey, Pennsylvania, 17033, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Reading the Brain's signals to predict who benefits from deep brain stimulation
- Ultrasound maps gluteal muscle to improve depot injection safety
- Could Nutri-Score menu labels be gentler than calorie counts for people with eating disorders?
- Can nicotine pouches help smokers quit?
- Could a Web-Based therapy ease common mental health struggles?
- Can a pressurized oxygen chamber keep brain benefits alive months later?